Niagen Bioscience, Inc. — Director's Dealing 2021

Mar 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2021-03-15

Reporting Person: BLOCK STEPHEN A (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-15	Common Stock	M	32500	$1.92	Acquired	49167	Direct
2021-03-15	Common Stock	S	32500	$11.15	Disposed	16667	Direct
2021-03-16	Common Stock	M	20000	$2.605	Acquired	36667	Direct
2021-03-16	Common Stock	S	20000	$13.17	Disposed	16667	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-15	Stock Options (right to buy)	$1.92	M	32500	Disposed	2022-08-27	Common Stock (32500)	Direct
2021-03-16	Stock Options (right to buy)	$2.605	M	20000	Disposed	2026-11-15	Common Stock (20000)	Direct

Footnotes

F1: The weighted average sale price for the transaction reported was $11.15, and the range of prices were between $11.10 and $11.25. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F2: The weighted average sale price for the transaction reported was $13.17, and the range of prices were between $13.10 and $13.34. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F3: The Options were granted on August 28, 2012 and vested 1/12th monthly from the grant date.

F4: The options were granted on November 16, 2016 and 100% vested on November 16, 2017.